KRAS Mutations Testing in Colorectal Carcinoma Patients in Italy: From Guidelines to External Quality Assessment

被引:28
作者
Normanno, Nicola [1 ,2 ]
Pinto, Carmine [3 ]
Castiglione, Francesca [4 ]
Bardelli, Alberto [5 ]
Gambacorta, Marcello [6 ]
Botti, Gerardo [7 ]
Nappi, Oscar [8 ]
Siena, Salvatore [9 ]
Ciardiello, Fortunato [10 ]
Taddei, GianLuigi [4 ]
Marchetti, Antonio [11 ]
机构
[1] INT Fdn G Pascale, Cell Biol & Biotherapy Unit, Naples, Italy
[2] CROM Ctr Ric Oncol Mercogliano, Pharmacogen Lab, Avellino, Italy
[3] St Orsola Marcello Malpighi Hosp, Bologna, Italy
[4] Univ Florence, Dept Human Pathol & Oncol, Florence, Italy
[5] Univ Turin, Inst Canc Res & Treatment, Turin, Italy
[6] Osped Niguarda Ca Granda, Div Pathol, Milan, Italy
[7] INT Fdn G Pascale, Surg Pathol Unit, Naples, Italy
[8] Antonio Cardarelli Hosp, Naples, Italy
[9] Osped Niguarda Ca Granda, Dept Oncol, Falck Div Med Oncol, Milan, Italy
[10] Univ Naples 2, Dept Expt & Clin Med & Surg F Magrassi & A Lanzar, Naples, Italy
[11] Univ Fdn, Ctr Excellence Aging, Ctr Predict Mol Med, Chieti, Italy
关键词
1ST-LINE TREATMENT; PHASE-III; CANCER; CETUXIMAB; FLUOROURACIL; LEUCOVORIN; PANITUMUMAB; OXALIPLATIN; IRINOTECAN; EFFICACY;
D O I
10.1371/journal.pone.0029146
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background: Monoclonal antibodies directed against the epidermal growth factor receptor (EGFR) have been approved for the treatment of patients with metastatic colorectal carcinoma (mCRC) that do not carry KRAS mutations. Therefore, KRAS testing has become mandatory to chose the most appropriate therapy for these patients. Methodology/Principal Findings: In order to guarantee the possibility for mCRC patients to receive an high quality KRAS testing in every Italian region, the Italian Association of Medical Oncology (AIOM) and the Italian Society of Pathology and Cytopathology -Italian division of the International Academy of Pathology (SIAPEC-IAP) started a program to improve KRAS testing. AIOM and SIAPEC identified a large panel of Italian medical oncologists, pathologists and molecular biologists that outlined guidelines for KRAS testing in mCRC patients. These guidelines include specific information on the target patient population, the biological material for molecular analysis, the extraction of DNA, and the methods for the mutational analysis that are summarized in this paper. Following the publication of the guidelines, the scientific societies started an external quality assessment scheme for KRAS testing. Five CRC specimens with known KRAS mutation status were sent to the 59 centers that participated to the program. The samples were validated by three referral laboratories. The participating laboratories were allowed to use their own preferred method for DNA extraction and mutational analysis and were asked to report the results within 4 weeks. The limit to pass the quality assessment was set at 100% of true responses. In the first round, only two centers did not pass (3%). The two centers were offered to participate to a second round and both centers failed again to pass. Conclusions: The results of this first Italian quality assessment for KRAS testing suggest that KRAS mutational analysis is performed with good quality in the majority of Italian centers.
引用
收藏
页数:6
相关论文
共 19 条
[1]   Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer [J].
Amado, Rafael G. ;
Wolf, Michael ;
Peeters, Marc ;
Van Cutsem, Eric ;
Siena, Salvatore ;
Freeman, Daniel J. ;
Juan, Todd ;
Sikorski, Robert ;
Suggs, Sid ;
Radinsky, Robert ;
Patterson, Scott D. ;
Chang, David D. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (10) :1626-1634
[2]   Prevalence and Heterogeneity of KRAS, BRAF, and PIK3CA Mutations in Primary Colorectal Adenocarcinomas and Their Corresponding Metastases [J].
Baldus, Stephan E. ;
Schaefer, Karl-L. ;
Engers, Rainer ;
Hartleb, Dinah ;
Stoecklein, Nikolas H. ;
Gabbert, Helmut E. .
CLINICAL CANCER RESEARCH, 2010, 16 (03) :790-799
[3]   External Quality Assessment for KRAS Testing Is Needed: Setup of a European Program and Report of the First Joined Regional Quality Assessment Rounds [J].
Bellon, Ellen ;
Ligtenberg, Marjolijn J. L. ;
Tejpar, Sabine ;
Cox, Karen ;
de Hertogh, Gert ;
de Stricker, Karin ;
Edsjo, Anders ;
Gorgoulis, Vassilis ;
Hofler, Gerald ;
Jung, Andreas ;
Kotsinas, Athanassios ;
Laurent-Puig, Pierre ;
Lopez-Rios, Fernando ;
Hansen, Tine Plato ;
Rouleau, Etienne ;
Vandenberghe, Peter ;
van Krieken, Johan J. M. ;
Dequeker, Elisabeth .
ONCOLOGIST, 2011, 16 (04) :467-478
[4]   Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study [J].
Bokemeyer, C. ;
Bondarenko, I. ;
Hartmann, J. T. ;
de Braud, F. ;
Schuch, G. ;
Zubel, A. ;
Celik, I. ;
Schlichting, M. ;
Koralewski, P. .
ANNALS OF ONCOLOGY, 2011, 22 (07) :1535-1546
[5]   Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer [J].
Bokemeyer, Carsten ;
Bondarenko, Igor ;
Makhson, Anatoly ;
Hartmann, Joerg T. ;
Aparicio, Jorge ;
de Braud, Filippo ;
Donea, Serban ;
Ludwig, Heinz ;
Schuch, Gunter ;
Stroh, Christopher ;
Loos, Anja H. ;
Zubel, Angela ;
Koralewski, Piotr .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (05) :663-671
[6]  
Carotenuto P, 2010, PHARMACOGENOMICS, V11, P1169, DOI [10.2217/pgs.10.86, 10.2217/PGS.10.86]
[7]   Uptake of KRAS mutation testing in patients with metastatic colorectal cancer in Europe, Latin America and Asia [J].
Ciardiello, Fortunato ;
Tejpar, Sabine ;
Normanno, Nicola ;
Mercadante, Domenica ;
Teague, Tracey ;
Wohlschlegel, Bruno ;
Van Cutsem, Eric .
TARGETED ONCOLOGY, 2011, 6 (03) :133-145
[8]   Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study [J].
Douillard, Jean-Yves ;
Siena, Salvatore ;
Cassidy, James ;
Tabernero, Josep ;
Burkes, Ronald ;
Barugel, Mario ;
Humblet, Yves ;
Bodoky, Gyoergy ;
Cunningham, David ;
Jassem, Jacek ;
Rivera, Fernando ;
Kocakova, Ilona ;
Ruff, Paul ;
Blasinska-Morawiec, Maria ;
Smakal, Martin ;
Canon, Jean-Luc ;
Rother, Mark ;
Oliner, Kelly S. ;
Wolf, Michael ;
Gansert, Jennifer .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (31) :4697-4705
[9]   A GENETIC MODEL FOR COLORECTAL TUMORIGENESIS [J].
FEARON, ER ;
VOGELSTEIN, B .
CELL, 1990, 61 (05) :759-767
[10]  
Jung A, 2009, J CLIN ONCOL S, V27, p15s